Tinavi Medical Technologies Co.,Ltd. (SHA:688277)
China · Delayed Price · Currency is CNY 25.06
-0.09 (-0.36%)
Feb 13, 2026, 3:00 PM CST
SHA:688277 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 267.95 | 172.59 | 206.71 | 145.48 | 145.6 | 126.88 |
Other Revenue | 6.25 | 6.25 | 3.33 | 10.71 | 10.43 | 9.03 |
| 274.2 | 178.84 | 210.04 | 156.19 | 156.02 | 135.91 | |
Revenue Growth (YoY) | 62.74% | -14.85% | 34.48% | 0.11% | 14.80% | -40.80% |
Cost of Revenue | 79.08 | 54.18 | 71.11 | 54.02 | 50.04 | 31.72 |
Gross Profit | 195.11 | 124.66 | 138.92 | 102.17 | 105.98 | 104.19 |
Selling, General & Admin | 256.05 | 188.11 | 217.47 | 164.98 | 140.57 | 141.33 |
Research & Development | 96.94 | 85.6 | 134.5 | 114.59 | 101.61 | 69.44 |
Other Operating Expenses | -21.14 | 2.48 | -3.84 | -0.3 | -1.27 | -6.95 |
Operating Expenses | 334.07 | 282.39 | 350.52 | 277.04 | 246.84 | 204.76 |
Operating Income | -138.95 | -157.73 | -211.6 | -174.87 | -140.86 | -100.57 |
Interest Expense | -7.33 | -9.14 | -6.43 | -3.95 | -3.35 | - |
Interest & Investment Income | 8.52 | 41.39 | 58.97 | 1.36 | 8.73 | 8.38 |
Currency Exchange Gain (Loss) | 1.16 | 1.16 | 0.72 | 3.15 | -0.9 | - |
Other Non Operating Income (Expenses) | -2.91 | -0.09 | -0.06 | -0.04 | -0.05 | -0.06 |
EBT Excluding Unusual Items | -139.52 | -124.42 | -158.39 | -174.36 | -136.43 | -92.25 |
Gain (Loss) on Sale of Investments | -6.73 | 0.05 | 0.09 | 0.1 | 0.63 | 0.95 |
Gain (Loss) on Sale of Assets | -0.04 | 5.39 | -0.03 | -0.05 | -0.17 | -0.73 |
Asset Writedown | 1.37 | - | - | - | - | -0.82 |
Other Unusual Items | 19.44 | 19.44 | 7.65 | 30.15 | 31.32 | 24.44 |
Pretax Income | -125.46 | -99.55 | -150.69 | -144.16 | -104.65 | -68.4 |
Income Tax Expense | 44.56 | 21.58 | 10.61 | -31.82 | -22 | -14.23 |
Earnings From Continuing Operations | -170.02 | -121.13 | -161.3 | -112.34 | -82.65 | -54.16 |
Minority Interest in Earnings | 11.01 | - | 4.91 | 1.75 | 2.72 | -0.31 |
Net Income | -159.01 | -121.13 | -156.39 | -110.58 | -79.93 | -54.47 |
Net Income to Common | -159.01 | -121.13 | -156.39 | -110.58 | -79.93 | -54.47 |
Shares Outstanding (Basic) | 455 | 449 | 447 | 425 | 421 | 389 |
Shares Outstanding (Diluted) | 455 | 449 | 447 | 425 | 421 | 389 |
Shares Change (YoY) | 2.19% | 0.40% | 5.05% | 1.10% | 8.13% | 0.54% |
EPS (Basic) | -0.35 | -0.27 | -0.35 | -0.26 | -0.19 | -0.14 |
EPS (Diluted) | -0.35 | -0.27 | -0.35 | -0.26 | -0.19 | -0.14 |
Free Cash Flow | -29.15 | -135.34 | -391.53 | -147.1 | -316.42 | -189.75 |
Free Cash Flow Per Share | -0.06 | -0.30 | -0.88 | -0.35 | -0.75 | -0.49 |
Gross Margin | 71.16% | 69.70% | 66.14% | 65.42% | 67.93% | 76.66% |
Operating Margin | -50.68% | -88.20% | -100.74% | -111.96% | -90.28% | -73.99% |
Profit Margin | -57.99% | -67.73% | -74.46% | -70.80% | -51.23% | -40.08% |
Free Cash Flow Margin | -10.63% | -75.68% | -186.41% | -94.18% | -202.80% | -139.61% |
EBITDA | -101.13 | -125.83 | -187.6 | -157.52 | -130.04 | -92.31 |
EBITDA Margin | -36.88% | -70.36% | -89.32% | -100.85% | -83.35% | -67.92% |
D&A For EBITDA | 37.82 | 31.9 | 24 | 17.35 | 10.82 | 8.25 |
EBIT | -138.95 | -157.73 | -211.6 | -174.87 | -140.86 | -100.57 |
EBIT Margin | -50.68% | -88.20% | -100.74% | -111.96% | -90.28% | -73.99% |
Revenue as Reported | 274.2 | 178.84 | 210.04 | 156.19 | 156.02 | 135.91 |
Advertising Expenses | - | 1.59 | 2.27 | 1.91 | 2.36 | - |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.